Compugen Ltd. (CGEN) |
|
0.702 -0.018 (-2.47%)
|
03-31 16:00 |
|
Open: |
0.71 |
Pre. Close: |
0.7198 |
|
High:
|
0.735 |
Low:
|
0.7 |
|
Volume:
|
80,333 |
Market Cap:
|
61(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:17:32 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 0.95 One year: 1.05 |
| Support: |
Support1: 0.68 Support2: 0.56 |
| Resistance: |
Resistance1: 0.81 Resistance2: 0.89 |
| Pivot: |
0.72 |
| Moving Average: |
MA(5): 0.71  MA(20): 0.74
MA(100): 0.85 MA(250): 1.29 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 21.3 %D(3): 22 |
| RSI: |
RSI(14): 42.3 |
| 52-week: |
High: 3.25 Low: 0.5 |
| Average Vol(K): |
3-Month: 455 (K) 10-Days: 202 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CGEN ] has closed above bottom band by 25.8%. Bollinger Bands are 64.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.74 - 0.74 |
0.74 - 0.74 |
|
Low:
|
0.69 - 0.69 |
0.69 - 0.7 |
|
Close:
|
0.71 - 0.72 |
0.72 - 0.73 |
|
Company Description |
|
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel. |
Headline News |
Wed, 15 Mar 2023
Compugen to Present New Research Enabling Accurate Detection and Study of Novel Target PVRIG at AACR 2023 - Yahoo Finance
Sun, 12 Mar 2023
Silicon Valley Bank – The Aftermath. Which Companies Were ... - TipRanks
Sun, 12 Mar 2023
Israel stocks slip on SVB failure, government vows aid for tech firms - The Jerusalem Post
Thu, 09 Mar 2023
Compugen Ltd. (NASDAQ:CGEN) Q4 2022 Earnings Call Transcript - Yahoo Finance
Wed, 08 Mar 2023
Study Investigates Anti-TIGIT Therapy Plus Pembrolizumab in ... - Targeted Oncology
Mon, 06 Mar 2023
Compugen Doses First Patient in Triple Combination COM701 ... - PR Newswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
87 (M) |
| Shares Float |
80 (M) |
|
% Held by Insiders
|
5.5 (%) |
|
% Held by Institutions
|
19.8 (%) |
|
Shares Short
|
2,090 (K) |
|
Shares Short P.Month
|
1,870 (K) |
Stock Financials |
|
EPS
|
-0.37 |
|
EPS Est Next Qtl
|
-0.19 |
|
EPS Est This Year
|
-0.74 |
|
EPS Est Next Year
|
-0.83 |
|
Book Value (p.s.)
|
0.89 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-471.7 |
|
Return on Assets (ttm)
|
-19.6 |
|
Return on Equity (ttm)
|
-36.6 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0.07 |
|
Sales Per Share
|
0.08 |
|
EBITDA (p.s.)
|
-0.41 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-35 (M) |
|
Levered Free Cash Flow
|
-19 (M) |
Stock Valuations |
|
PE Ratio
|
-1.95 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.78 |
|
Price to Sales
|
8.1 |
|
Price to Cash Flow
|
-1.77 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
